ASTRAZENECA PLC (AZN) Form 10-K Annual Reports
ASTRAZENECA PLC (AZN) is a publicly traded company on the NYSE, categorized under SIC 2834 (Pharmaceutical Preparations). Access real-time SEC filings, 10-K annual reports, 10-Q quarterlies, 8-K current reports, PCAOB auditor history, and executive compensation disclosures.
Ticker: AZN
CIK: 901832
Exchange: NYSE
SIC 2834: Pharmaceutical Preparations
Fiscal Year End: 12/31
State: X0
Independent PCAOB Auditor
Explore PCAOB Audit Intelligence →
Audit Firm
PricewaterhouseCoopers LLP
Auditor SinceSince 12/31/2017 12:00:00 AM
Lead Engagement PartnerSarah Quinn
Audit LocationLondon, United Kingdom
Latest SEC EDGAR Filings
Showing 10-K, 10-Q, 8-K, Form 4, and other SEC submissions| Form | Filing Date | Reporting Period | Description | Accession Number | Actions |
|---|---|---|---|---|---|
| 4 | 2026-10-08 | 2026-10-06 | PRIMARY DOCUMENT | 0002122411-26-000002 | View SEC Doc Filr Page |
| 6-K | 2026-10-05 | 2026-10-05 | ASTRAZENECA COMPLETES EQUITY INVESTMENT IN SUMMIT | 0001654954-26-008783 | View SEC Doc Filr Page |
| 6-K | 2026-10-02 | 2026-10-02 | AZ & DS COLLABORATION WITH SUMMIT FOR DATROWAY | 0001654954-26-008760 | View SEC Doc Filr Page |
| 6-K | 2026-10-01 | 2026-10-01 | ADMISSION OF FURTHER SECURITIES TO TRADING | 0001654954-26-008741 | View SEC Doc Filr Page |
| 6-K | 2026-10-01 | 2026-10-01 | TOTAL VOTING RIGHTS | 0001654954-26-008739 | View SEC Doc Filr Page |
| 6-K | 2026-09-29 | 2026-09-29 | ASTRAZENECA ANNOUNCES EQUITY INVESTMENT IN SUMMIT | 0001654954-26-008615 | View SEC Doc Filr Page |
| 6-K | 2026-09-23 | 2026-09-23 | TRIXEO APPROVED IN EU FOR ASTHMA | 0001654954-26-008520 | View SEC Doc Filr Page |
| 6-K | 2026-09-21 | 2026-09-21 | KLYGEFA RECOMMENDED FOR EU APPROVAL BY CHMP | 0001654954-26-008478 | View SEC Doc Filr Page |
| 6-K | 2026-09-21 | 2026-09-21 | ENHERTU RECOMMENDED FOR APPROVAL IN EU IN EARLY BC | 0001654954-26-008476 | View SEC Doc Filr Page |
| 6-K | 2026-09-18 | 2026-09-18 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008438 | View SEC Doc Filr Page |
| 6-K | 2026-09-15 | 2026-09-15 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008369 | View SEC Doc Filr Page |
| 6-K | 2026-09-15 | 2026-09-15 | DIRECTOR/PDMR SHAREHOLDING | 0001654954-26-008367 | View SEC Doc Filr Page |
| 6-K | 2026-09-14 | 2026-09-14 | UPDATE ON SERENA-4 PHASE III TRIAL | 0001654954-26-008323 | View SEC Doc Filr Page |
| 4 | 2026-09-11 | 2026-08-08 | OWNERSHIP DOCUMENT | 0001104659-26-107055 | View SEC Doc Filr Page |
| 6-K | 2026-09-08 | 2026-09-08 | IMFINZI+IMDELLTRA IMPROVED OS IN SMALL CELL LUNG | 0001654954-26-008172 | View SEC Doc Filr Page |
| 6-K | 2026-09-08 | 2026-09-08 | ETCAMAH APPROVED IN THE US FOR HR+ BREAST CANCER | 0001654954-26-008150 | View SEC Doc Filr Page |
| 6-K | 2026-09-01 | 2026-09-01 | ADMISSION OF FURTHER SECURITIES TO TRADING | 0001654954-26-008042 | View SEC Doc Filr Page |
| 6-K | 2026-09-01 | 2026-09-01 | TOTAL VOTING RIGHTS | 0001654954-26-008040 | View SEC Doc Filr Page |
| 6-K | 2026-09-01 | 2026-09-01 | ADMISSION TO TRADING - EUR2.55 BILLION BOND OFFERING | 0001654954-26-007992 | View SEC Doc Filr Page |
| 6-K | 2026-09-01 | 2026-09-01 | ENHERTU APPROVED IN EU FOR 1L HER2-POSITIVE MBC | 0001654954-26-007990 | View SEC Doc Filr Page |
| 6-K | 2026-09-01 | 2026-09-01 | DIRECTORATE CHANGE | 0001654954-26-007988 | View SEC Doc Filr Page |
| 6-K | 2026-09-01 | 2026-09-01 | ASTRAZENECA COMPLETES AGREEMENT FOR ZEGFROVY | 0001654954-26-007986 | View SEC Doc Filr Page |
| 6-K | 2026-09-01 | 2026-09-01 | TAGRISSO + ORPATHYS IMPROVED PFS IN 1L EGFRM LUNG | 0001654954-26-007983 | View SEC Doc Filr Page |
| 6-K | 2026-08-27 | 2026-08-27 | TEZSPIRE CROSSING TRIAL MET PRIMARY ENDPOINTS | 0001654954-26-007894 | View SEC Doc Filr Page |
| 6-K | 2026-08-25 | 2026-08-25 | ASTRAZENECA PRICES A EUR2.55 BILLION BOND OFFERING | 0001654954-26-007840 | View SEC Doc Filr Page |